SG11201811160XA - Treatment for myopia - Google Patents

Treatment for myopia

Info

Publication number
SG11201811160XA
SG11201811160XA SG11201811160XA SG11201811160XA SG11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA
Authority
SG
Singapore
Prior art keywords
international
myopia
pct
new south
south wales
Prior art date
Application number
SG11201811160XA
Inventor
Sally Anne Mcfadden
Original Assignee
Univ Newcastle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016902429A external-priority patent/AU2016902429A0/en
Application filed by Univ Newcastle filed Critical Univ Newcastle
Publication of SG11201811160XA publication Critical patent/SG11201811160XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 December 2017 (28.12.2017) WIP0 I PCT Iiiimmomiolollmolomm VIII iflo Hs (10) International Publication Number WO 2017/219080 Al 1-1 GC 1-1 N 1-1 O O (51) International Patent Classification: A61K 31/198 (2006.01) A61P 27/02 (2006.01) A61K 31/04 (2006.01) (21) International Application Number: PCT/AU2017/050627 (22) International Filing Date: 21 June 2017 (21.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016902429 21 June 2016 (21.06.2016) AU (71) Applicant: THE UNIVERSITY OF NEWCASTLE [AU/AU]; 130 University Drive, Callaghan, New South Wales 2308 (AU). (72) Inventor: MCFADDEN, Sally Anne; 56 Dawson Street, Cooks Hill, New South Wales 2300 (AU). (74) Agent: DAVIES COLLISON CAVE PTY LTD; 255 Elizabeth Street, Sydney, New South Wales 2000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) = (54) Title: TREATMENT FOR MYOPIA FIGURE 1 A B Diffe re nce in Refrac t ive Erro r ( D) Diffe re nce in Ocu la Le r ng t h (p. m) 150 100 50 0 -50 - 100 - 150 -6D Plano Rec -6D Plano Rec (57) : Provided herein are methods for treating or preventing myopia, or for inhibiting the development of myopia, comprising administering to a subject in need thereof an effective amount of an agent capable of increasing nitric oxide levels in one or more ocular cells or an agent capable of promoting or increasing the expression and/or activity of nNOS in one or more ocular cells. Also provided are methods for inducing or promoting nNOS expression and/or activity in one or more ocular cells, comprising exposing said cells to an effective amount of L-arginine.
SG11201811160XA 2016-06-21 2017-06-21 Treatment for myopia SG11201811160XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016902429A AU2016902429A0 (en) 2016-06-21 Treatment for myopia
PCT/AU2017/050627 WO2017219080A1 (en) 2016-06-21 2017-06-21 Treatment for myopia

Publications (1)

Publication Number Publication Date
SG11201811160XA true SG11201811160XA (en) 2019-01-30

Family

ID=60783610

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811160XA SG11201811160XA (en) 2016-06-21 2017-06-21 Treatment for myopia

Country Status (4)

Country Link
US (1) US10945980B2 (en)
CN (1) CN109640973A (en)
SG (1) SG11201811160XA (en)
WO (1) WO2017219080A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763280A1 (en) * 2019-07-11 2021-01-13 Carl Zeiss Vision International GmbH Determination of a change in the refraction error of an eye
CN110934865A (en) * 2019-12-06 2020-03-31 牡丹江医学院 Pharmaceutical composition for preventing and treating hemodialysis hypotension and application thereof
EP4157453A1 (en) * 2020-06-02 2023-04-05 The Trustees of Columbia University in the City of New York Methods and compositions for preventing and treating myopia with levocabastine, a selective histamine h1-receptor antagonist, and derivatives thereof
JP2023529943A (en) * 2020-06-11 2023-07-12 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク Methods and compositions for preventing and treating myopia using S-methyl-L-thiocitrulline, a selective neuronal nitric oxide synthase (NNOS) inhibitor, and derivatives thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
CN1390124A (en) * 2000-09-20 2003-01-08 永光制药有限公司 Medicine for preventing or treating myopia
RU2635185C2 (en) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Pharmaceutical preparation for prevention and treatment of progressive myopia

Also Published As

Publication number Publication date
US20190142778A1 (en) 2019-05-16
US10945980B2 (en) 2021-03-16
CN109640973A (en) 2019-04-16
WO2017219080A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201906161VA (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201908857QA (en) Methods for the treatment of inflammation and inflammatory conditions
SG11201811160XA (en) Treatment for myopia
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201810443SA (en) Invasive medical devices including magnetic region and systems and methods
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201809341PA (en) Mobile robot
SG11201805381TA (en) Electroporation device with detachable needle array with lock-out system
SG11201809605PA (en) Compositions for and method of treating acid-base disorders
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201900057WA (en) Biomatrix scaffolds for use in diagnosing and modeling cancer
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201805184TA (en) Combination therapy
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201809882XA (en) Pharmaceutical combinations for treating cancer